The key questions addressed in this summary are whether clot removal should be part of the preferred therapy for patients with acute deep venous thrombosis (DVT), and whether there is evidence that a strategy of thrombus removal offers better outcomes for patients than anticoagulation alone. Evidence is defined as an outward sign or something that furnishes proof. Evidence in medicine is not limited to direct, blinded comparisons of one form of treatment compared with another but rather the body of knowledge that provides insight to clinicians to offer patient care. Evidence-based medicine follows from information available to form the foundation for the use of a treatment for a specific disease. Reports of strategies of thrombus removal for acute DVT, especially in patients with iliofemoral DVT, consistently demonstrate improved outcomes relative to postthrombotic morbidity. This summary reviews the evidence supporting this strategy as the preferred initial management of patients with extensive proximal DVT. ( J Vasc Surg 2012;55: 607-11.)
Extensive deep venous thrombosis (DVT) of the lower extremity is associated with severe postthrombotic morbidity and increased rates of recurrence. Although robust randomized trials have not yet been completed, there is a large body of evidence supporting a strategy of thrombus removal. The overwhelming number of patients today are treated with catheter-based interventions to eliminate their extensive venous thrombosis.
Depending upon the extent of acute DVT, postthrombotic syndrome has been reported in 25% to 46% of patients. 1, 2 However, patients with iliofemoral DVT who occlude their single venous outflow tract from the lower extremity have the most severe postthrombotic morbidity. 3, 4 A recent prospective analysis demonstrated that acute iliofemoral DVT predisposed to postthrombotic syndrome more frequently than infrainguinal DVT. 5 Large observational studies have underscored the importance of recurrence being associated with increasingly severe postthrombotic syndrome. 2 Investigators have shown that patients with residual venous thrombus 6 and increasing thrombus activity 7 have significantly higher rates of recurrent venous thrombosis. Aziz et al 8 recently reported that recurrent DVT following catheter-directed thrombolysis (CDT; for iliofemoral DVT) correlated with the amount of residual thrombus at the end of treatment.
Given the severe morbidity of iliofemoral DVT and the benefit of thrombus removal demonstrated by natural history studies, observational reports, and randomized trials, there appears to be objective evidence supporting a strategy of thrombus removal.
METHODS
Studies were identified by searching the MEDLINE database for all reports evaluating the use of catheter-based techniques for treatment of acute lower extremity DVT. Catheter-based strategies included intrathrombus CDT, where the plasminogen activator is infused directly into the clot, and pharmacomechanical thrombolysis (or thrombectomy), which incorporates the use of adjunctive mechanical methods to clear the clot. Only studies consisting of Ն25 patients or limbs were included in the analysis.
Studies of systemic thrombolysis (via peripheral intravenous administration) were excluded from this review, as catheter-based procedures have rapidly replaced systemic thrombolysis as the preferred method of treating patients with extensive DVT.
RESULTS
Twenty studies meeting the search criteria were identified (Table) . [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Eighteen studies were observational, and two were from randomized controlled trials comparing catheter-based techniques plus anticoagulation with anticoagulation alone. Seventeen studies focused entirely on patients with lower extremity DVT, and three studies included a small number of upper extremity DVT patients.
Catheter-directed thrombolysis is generally associated with an 80% to 90% success rate, with bleeding complications in the 5% to 11% range. Most bleeding complications are puncture-site hematomas, with few distant bleeding complications. Intracranial bleeding was not observed in the majority of studies and represents a rare complication of CDT for venous thrombosis. Symptomatic pulmonary embolism (PE) during CDT has been reported in approximately 1%; however, fatal PE is also rare.
In a report of 103 patients with iliofemoral DVT treated with CDT, Baekgaard and colleagues 25 found that 86% of their patients had patent veins and normal valve function at 6-year follow-up. Furthermore, only 6% of their patients suffered a recurrence during the follow-up period.
Pharmacomechanical techniques are increasing in popularity and include use of rheolytic thrombolysis, ultrasound-accelerated thrombolysis, and isolated segmental pharmacomechanical thrombolysis. Using these techniques, authors have reported better overall success, shorter treatment times, reduced dose of plasminogen activator, shorter intensive care unit stays, and reduced blood loss. 20, 22, 23 The results of two randomized trials have been reported, including a small trial from Egypt 14 and the preliminary observations from the first 103 patients randomized in the Catheter-directed Venous Thrombolysis (CaVenT) trial.
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Egypt trial. The first randomized trial of CDT versus anticoagulation for acute iliofemoral DVT was reported by Elsharawy and Elzayat.
14 Thirty-five patients were randomized to either CDT followed by anticoagulation or anticoagulation alone. Streptokinase was the chosen plasminogen activator, which was initially infused into the clot using a pulse-spray technique followed by a continuous catheterdirected infusion. Patients underwent phlebography at 12-hour intervals. CDT was terminated following complete lysis or when no progress was observed on interval phlebography. Patients randomized to anticoagulation alone were treated with unfractionated heparin (UFH) according to protocol and converted to oral anticoagulation with warfarin to achieve a target International Normalized Ratio (INR) of 2.0 to 3.0.
Outcome at 6 months demonstrated that iliofemoral patency was observed in 72% of patients who received thrombolysis versus 12% randomized to anticoagulation (P Ͻ .001). Valvular function was normal in 89% of lytic patients versus 59% of those receiving anticoagulation alone (P ϭ .04). Complications were minimal in both groups. Three patients (17%) in the thrombolysis group had a high fever, which is the pyretic side effect of streptokinase. There were no major bleeding complications and no mortality.
CaVenT trial. The CaVenT study is a randomized, multicenter trial of CDT plus anticoagulation versus anticoagulation alone for patients with iliofemoral DVT. 26 The trial was designed with two primary endpoints: (1) a longterm functional efficacy endpoint of postthrombotic syndrome at 24 months; and (2) a short-term descriptive efficacy endpoint focusing on patency after 6 months.
Patients with iliofemoral DVT with symptoms Ͻ21 days were randomized to anticoagulation alone or CDT. Those treated with anticoagulation alone received UFH and were transitioned to warfarin to a target INR of 2.0 to 3.0. Patients who received thrombolysis had the catheter inserted directly into the thrombus and were treated with intrathrombus infusion of tissue plasminogen activator (t-PA) at a dose of 0.01 mg/kg/hr, not to exceed 20 mg for a 24-hour period. Progress of thrombolysis was assessed with daily phlebography. Two major complications occurred in the lytic group: (1) a compartment syndrome of the calf as a result of vessel perforation and bleeding; and (2) impaired sensibility of the foot, likely due to trauma of a sensory nerve.
One hundred three patients were reported in the interim analysis. Fifty received CDT and 53 were treated with anticoagulation alone. At 6-month follow-up, iliofemoral patency was 64% in the lytic group versus 36% in the controls (P ϭ .004). Hemodynamic venous obstruction was found in 20% of the thrombolysis group versus 49% of the anticoagulation group (P ϭ .004). Valve function at 6 months did not differ between groups. Patency and hemodynamic results were similar to those reported in the Egypt study. Differences in venous valve function remain to be explained.
DISCUSSION
Natural history studies of acute DVT treated with anticoagulation alone have demonstrated that when endogenous fibrinolysis is efficient and resolves thrombus within 60 to 90 days, venous patency is restored, and valve function is preserved. 28 When observations were extended in the same patient cohort, recurrent venous thrombosis occurred at a significantly higher rate in patients in whom thrombus did not resolve. [29] [30] [31] Fibrinolytic agents are designed to pharmacologically lyse thrombus by activating plasminogen to the active enzyme plasmin. The basic mechanism of action of thrombolytic agents is activation of fibrin-bound plasminogen. (793) 0 (0) 18 (21) 11 (14) 5 (6) 1 0 96 (31) 162 (52) 54 (17) 15 (28) 54 (11) 6 2 (Ͻ1) 14 (26) 28 (52) 6 (11) 8 (15) 4 ( (72) 2 (12) 5 (28) 8 ( (81) 16 (84) 3 (11) 3 (16) 2 (8) 0 1 (4) 0 2 (7) 1 (5) 1 (4) 1 (5) 0 0 32 (70) 39 (75) 14 (30) 13 (25) 5 (11) 4 (8) 2 (4) 2 (4) 1 (2) Sherry et al 32 observed that the primary most effective mechanism for thrombolysis was the penetration of the plasminogen activator into the thrombus, followed by activation of plasminogen that binds to fibrin during the clotting process. 33 A case-controlled cohort study observed that patients with iliofemoral DVT treated with CDT have significantly better quality of life (QoL) at 16 and 22 months following treatment compared with patients managed with anticoagulation alone. 34 Grewal et al 35 reported that improved QoL was directly related to the success of catheter-directed lysis.
The Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-directed Thrombolysis (ATTRACT) trial, a phase 3, open-label, multicenter randomized controlled trial sponsored by the National Heart, Lung, and Blood Institute of the National Institutes of Health, is designed to answer a number of important clinical questions, including: (1) is a strategy of thrombus removal with catheter-based techniques more effective in reducing postthrombotic morbidity than anticoagulation alone in patients with iliofemoral DVT and in patients with femoropopliteal DVT; (2) are pharmacomechanical techniques more effective than drip infusion of plasminogen activators; (3) is treatment cost-effective; (4) what is the risk-to-benefit ratio of catheter-based techniques versus anticoagulation alone; and (5) is postthrombotic morbidity related to vein patency and/or venous valve function?
The trial is projected to randomize 696 patients with symptomatic proximal acute DVT to CDT (with or without pharmacomechanical techniques) plus anticoagulation versus anticoagulation alone, and patients will be stratified according to their proximal extents of thrombus (femoropopliteal vs iliofemoral; 
CONCLUSION
Catheter-based techniques are now the preferred method of managing patients with extensive venous thrombosis if a strategy of thrombus removal is chosen. Early results of observational studies suggest that patients benefit from such a strategy; however, the important endpoints of postthrombotic morbidity and QoL have only been reported observationally and not in randomized trials. It appears that catheter-based techniques are related to the amount of thrombus removed and that the reduction in postthrombotic morbidity (improvement in QoL) and even the risk of recurrent venous thrombosis is related to the success of thrombolysis.
A small randomized trial from Egypt supports a strategy of CDT versus anticoagulation alone as do the preliminary results of the CaVenT trial. The CaVenT trial is in the process of 2-year follow-up to assess their primary endpoint.
The ATTRACT trial will be the largest randomized trial when completed and should offer definitive answers regarding the value of CDT for venous thrombosis, segmenting patients by thrombus extent (iliofemoral vs femoropopliteal). 
